Professional biography

Dr. Marion Coe is Director of Clinical Development and Post-Marketing Surveillance at Pinney Associates, where she advises pharmaceutical and biotech companies on clinical development, drug regulation, and post-marketing risk management for medications with complex safety profiles. She holds a PhD in Pharmacology from the University of Kentucky. In over a decade of experience, including working in the human pharmacology lab at NIAAA to evaluate novel treatments for alcohol use disorder, Dr. Coe has established particular expertise in central nervous system (CNS) compounds, psychedelics, and medications with abuse potential.

Dr. Coe's work spans the development of treatments for post-traumatic stress disorder (PTSD), substance use disorders, depression, pain, and headache disorders. She has extensive experience in clinical trial design, FDA interactions, abuse potential assessment, and the development and implementation of Risk Evaluation and Mitigation Strategies (REMS).

In addition to her scientific and regulatory work, Dr. Coe is actively engaged in government affairs and public policy related to psychedelic drug development and access. She has provided invited briefings before Congress and has contributed to policy discussions concerning the responsible development, evaluation, and integration of psychedelic-assisted therapies into clinical care.